C12N 2770/32371
Demonstrated in vivo effect
C12N2770/32371 (Demonstrated in vivo effect) appears on 14 US grants and 25 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 25
- Assignees
- 19
- Inventors
- 56
- Latest grant
- 30 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 1 | 0 |
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 1 | 0 |
| 2015 | 0 | 2 |
| 2016 | 0 | 3 |
| 2017 | 0 | 3 |
| 2018 | 2 | 3 |
| 2019 | 0 | 5 |
| 2020 | 5 | 2 |
| 2021 | 0 | 0 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 0 | 2 |
| 2025 | 3 | 0 |
| 2026 | 0 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Antitumor virus30 Dec 2025US 12,508,291 B2Shanxi Academy of Advanced Research and Innovation
- Pharmaceutical composition containing stabilized nucleic acid adjuvant11 Nov 2025US 12,465,644 B2Sml Biopharm Co., Ltd.
- Adapted enterovirus D68 that propagates to high titer in vero cells6 May 2025US 12,290,555 B2Bharat Biotech International Limited
- Virus for treatment of tumor24 Oct 2023US 11,793,844 B2Xiamen University
- Combination method for treatment of cancer19 Jul 2022US 11,389,495 B2Merck Sharp & Dohme Corp.
- Bivalent inactivated ev71-ca16 vaccine, method for preparing the same, and use thereof12 Mar 2026US 2026/0069673 A1Aim Action Biopharm Co., Ltd
- Coxsackievirus 83 Vaccine8 Aug 2024US 2024/0261386 A1King Faisal University
- Mir-375- and mir-1-regulated coxsackievirus b3 has no pancreas and heart toxicity but strong antitumor efficiency in colorectal carcinomas1 Aug 2024US 2024/0252564 A1Technische UniversitäT Berlin
- Antitumor virus23 Feb 2023US 2023/0057747 A1Shanxi Academy of Advanced Research and Innovation
- Pharmaceutical composition containing stabilized nucleic acid adjuvant28 Jul 2022US 2022/0233700 A1Korea Institute of Science and Technology
Most cited
By later US patents